myopathy was the most common feature in our cohort of mitochondrial patients. Among the 722 patients with a definite genetic diagnosis, ocular myopathy was observed in 399 subjects (55.3%) and was positively associated with mtDNA single deletions and POLG mutations. Ocular myopathy as manifestation of a multisystem mitochondrial encephalomyopathy (PEO-encephalomyopathy, n = 131) was linked to the m.3243A>G mutation, whereas the other "PEO" patients (n = 268) were associated with mtDNA single deletion and Twinkle mutations. Increased lactate was associated with central neurological involvement. We then defined, among the PEO group, as "pure PEO" the patients with isolated ocular myopathy and "PEO-plus" those with ocular myopathy and other features of neuromuscular and multisystem involvement, excluding central nervous system. The male proportion was significantly lower in pure PEO than PEO-plus. This study reinforces Abstract Ocular myopathy, typically manifesting as progressive external ophthalmoplegia (PEO), is among the most common mitochondrial phenotypes. The purpose of this study is to better define the clinical phenotypes associated with ocular myopathy. This is a retrospective study on a large cohort from the database of the "Nation-wide Italian Collaborative Network of Mitochondrial Diseases". We distinguished patients with ocular myopathy as part of a multisystem mitochondrial encephalomyopathy (PEOencephalomyopathy), and then PEO with isolated ocular myopathy from PEO-plus when PEO was associated with additional features of multisystemic involvement. Ocular the need for research on the role of gender in mitochondrial diseases. The phenotype definitions here revisited may contribute to a more homogeneous patient categorization, useful in future studies and clinical trials.
Introduction
Mitochondrial disorders form a disease group characterized by impaired mitochondrial respiratory chain [1] . One of the most common phenotypes is an ocular myopathy known as progressive external ophthalmoplegia (PEO) and characterized by progressive bilateral ptosis and diffuse reduction in ocular motility.
In 1958, Kearns and Sayre highlighted the association between PEO, retinal degeneration, and heart block [2] . In 1968, Drachman coined the term, "ophthalmoplegiaplus", to emphasize the presence of co-morbidities associated with PEO [3] . Later, signs of mitochondrial dysfunction were observed in PEO, and this was clearly connected either with intrinsic alterations of mitochondrial DNA (mtDNA), i.e., sporadic heteroplasmic deletions or maternally inherited point mutations, or with autosomal dominant or recessive mutations in nuclear genes ultimately affecting mtDNA maintenance and integrity [4] .
However, there is no universally accepted definition of "PEO" [4] , even when a genetically homogeneous condition is considered (e.g., single deletion of muscle mtDNA) [1] . PEO has been deemed as a clinical hallmark of mitochondrial myopathy rather than a specific syndrome/disease, and it has been proposed that when PEO co-occurs with other symptoms of mitochondrial dysfunction should be defined as "PEO-plus syndrome" [4] . Even if PEO-plus is a term frequently utilized in the clinical setting to identify patients with PEO associated with some degree of multisystem involvement, a precise definition of this nosological entity is missing.
In the last three decades, mitochondrial medicine has been extremely successful in the characterization of the molecular and genetic basis of disease [1] . However, a better understanding of clinical mitochondrial phenotypes is a challenging but necessary task as well. Clinical variability is broad even in individuals with the same genotype and the statistical power is low in single-center studies, owing to the rarity of these conditions.
The purpose of the present study is to better define the clinical phenotypes associated with ocular myopathy in a large cohort of patients collected in the database of the "Nation-wide Italian Collaborative Network of Mitochondrial Diseases". This Network has previously been instrumental to redefine the clinical features of common mtDNA mutations (e.g., m.3243A>G [5] , m.8344A>G [6] , or single deletions [7] ) and to better elucidate some signs and symptoms of mitochondrial diseases including myoclonus [8] and peripheral neuropathy [9] .
Methods
Specific aims of this study were to (1) better characterize mitochondrial ocular myopathies and related phenotypes, (2) establish genotype-phenotype correlations, and (3) identify clinical and molecular predictive factors.
Among the 1300 patients included in our "Nation-wide Italian Collaborative Network of Mitochondrial Diseases" database (updated at January 1st, 2016), we reviewed the clinical data of the 1100 patients followed up by the involved centers, for whom histological, biochemical and/ or molecular data were available, in addition to well-documented clinical picture. For a detailed phenotype-genotype analysis focusing on ocular myopathy, we considered the 722 patients with a definitive genetic diagnosis, excluding patients with Leber hereditary optic neuropathy (LHON), which is usually limited to the optic nerve [1] without major multisystem involvement. Patients with histological and/or biochemical diagnosis or mtDNA multiple deletions with no identified nuclear or mtDNA gene mutation were not considered, because they were not suitable for genotype-phenotype analysis. This is a retrospective study. All the involved centers (both adult and pediatric) have specific expertise in mitochondrial disorders and other neuromuscular diseases. The clinical section of our web-based database includes "yes or no" dichotomic items agreed by all centers in a preliminary consensus phase, which was specifically designed to include the clinical features known to be relevant in mitochondrial medicine [1] . These items are shown elsewhere in detail [7] .
Data were expressed as mean ± standard deviation. Continuous variables (i.e., age at onset, disease duration) were compared by unpaired two-tailed Student's t test. Categorical data and proportions were analyzed by Fisher's exact test. Bonferroni's correction for multiple tests was applied when appropriate. A two-tailed P value <0.05 was considered as significant. Data analysis was carried out using MedCalc ® Version 7.3.0.1. The establishment of the database and its use for scientific purposes were approved by the local Ethical Committees of all the involved Centers, which obtained written consent from each patient, in accordance with the ethical standards of the 1964 Declaration of Helsinki.
This work was supported by Telethon (Grant numbers GUP09004 and GSP16001).
Results

Preliminary data
Among the 1300 patients present in our database, 1100 individuals had a fully reported clinical picture, irrespective of the presence or absence of a genetic diagnosis. In these 1100 individuals, the mean age at onset was 24.4 ± 20.5 years; age at last evaluation 39.8 ± 22.3 years; childhood onset (before age 16) 43.8%; male proportion 48%. Ocular myopathy, with eyelid ptosis and/or ophthalmoparesis, was the first clinical feature observed in 471/1100 patients (42.8%). If we exclude LHON patients, ocular myopathy was present in 470/965 (48.7%). Only one LHON patient (1/135, 0.7%) had ptosis, confirming the assumption stated in "Methods".
Association with specific genotypes
Among the 722 patients with a definite genetic diagnosis ( Fig. 1) , the term "ocular myopathy" was present in 399 cases (55.3%), being positively associated with mtDNA single deletions and POLG mutations (Table 1) . Ocular myopathy was less common in patients with OPA1 mutations and all the mtDNA point mutations (see Table 1 ).
Ocular myopathy:encephalomyopathy versus "PEO"
Among our 399 patients with ocular myopathy, a first group of 131 individuals (32.8%) had also an encephalomyopathy ("PEO-encephalomyopathy"), whereas a second group of 268 individuals (67.2%) had no sign of central nervous system (CNS) disease, and were therefore defined simply as "PEO" (see Fig. 1 ). These included also the PEO patients with psychiatric involvement and migraine but no other signs of CNS impairment, as these symptoms (very frequent also in otherwise healthy people) were not considered sufficient to define an encephalomyopathy. The first, "PEO-encephalomyopathy" group had a mean age at onset of 17.6 ± 18.3 years, the age at last evaluation was 32.6 ± 23.1 years, the male proportion was 64/131 (48.9%); the disease duration was 16.6 ± 13.8 years. The second, "PEO" group had a mean age at onset of 28.1 ± 15.9 years, the age at last evaluation was 45.4 ± 17.0 years, the male proportion was 100/268 (37.3%); the disease duration was 20.8 ± 15.1. Age at onset was higher in the PEO group (P < 0.05). The difference in male proportion (higher in the PEO-encephalomyopathic group) was also significant (P = 0.03), and is fully explained by the already known increased proportions of stroke-like episodes among m.3243A>G male patients [5] . As expected, there were more deceased patients in the "PEO-encephalomyopathy" (25/131) group than in the "PEO" group (10/268), with a P < 0.0001.
In the "PEO-encephalomyopathy" group, ocular myopathy was associated with the following CNS features (see Fig. 2 ): 79/399 ataxia (19.8%), 54 cognitive impairment (13.5%), 30 seizures (7.5%), 29 pyramidal signs (7.3%), 18 tremor (4.5%), 15 stroke-like episodes (3.8%), 15 impaired consciousness (3.8%), 14 dystonia (3.5%), 12 microcephaly (3.0%), 11 nystagmus (2.8%), 9 myoclonus (2.3%), 8 parkinsonism (2.0%). We did not observe any specific syndromic association of ocular myopathy with these CNS features, apart a negative association with seizures (Online resource Table e-1).
In the "PEO-encephalomyopathy" group, there was an increased prevalence of m.3243A>G carriers, whereas single deletions and Twinkle (TWK) mutations were associated with the "PEO" phenotype (Table 2) . Other rare nuclear and mtDNA mutations were usually associated with PEO-encephalomyopathic features. In those patients in whom muscle biopsy has been performed, ragged red fibers (RRF) were equally frequent in the PEO group (153/189, 81.0%) versus PEO-encephalomyopathy group (64/90, 71.1%), whereas there was a border-line difference in cytochrome c oxidase (COX)-negative fibers, which were more frequent in the "PEO" group than in the "PEO-encephalomyopathy" group [respectively, 167/189 (88.4%) and 69/90 (76.7%); P = 0.02 (significance level after Bonferroni's correction 0.025)].
Increased lactate levels were more frequently detected in the PEO-encephalomyopathy group (P < 0.000001) (Online resource Table e-2). If we consider the 62 "encephalomyopathic" patients with a PEO onset, lactate was increased in 29/62 (46.8%), higher than the subjects with PEO who had never developed CNS disease (60/268, 22.4%), with a P = 0.0002.
The "PEO" group
Considering the 268 PEO patients, ocular myopathy was associated with the following features: 115 muscle weakness (42.9%), 62 exercise intolerance (23.1%), 47 muscle wasting (17.5%), 41 hearing loss (15.3%), and 40 swallowing impairment (14.9%). These signs and symptoms showed no association with specific genotypes, except for mutations in TYMP, the gene causing mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), which were associated with muscle wasting (Online resource Table  e-3) .
Rarer features (present in 2-15% of patients) were: increased CK levels (37 individuals, 13.8%), muscle pain (25 individuals, 9.3%), diabetes mellitus (20 individuals, 7.5%), respiratory impairment (16 individuals, 6.0%), heart conduction/rhythm defects (14 individuals, 5.2%), hypotonia (14 individuals, 5.2%), gastrointestinal dysmotility (12 individuals, 4.5%), cardiomyopathy (10 individuals, 3.7%), peripheral neuropathy (9 individuals, 3.4%), migraine (9 individuals, 3.4%), optic neuropathy (8 individuals, 3.0%), retinopathy (8 individuals, 3.0%), recurrent vomiting (8 individuals, 3.0%), short stature (8 individuals, 3.0%), and psychiatric involvement (6 individuals, 2.2%).
Patients with "pure" PEO (without any other features of multisystem disease) were 98/268 (36.6%). These patients did not show a different age at onset (28.5 ± 15.1 years) nor disease duration (22.3 ± 19.6 years) from the other PEO patients (see Fig. 1 ), who had at least one of the neuromuscular/multisystem features reported above (tentatively defined here as "PEO-plus"). The genotype proportions did not significantly differ. The male proportion was 26/98 (26.5%), lower than PEO-plus patients (P < 0.001) ( Table 3 ). Potentially confounding factors (genotype proportion, age at onset and at last evaluation, disease duration) did not differ significantly between males and females.
Discussion
Ocular myopathy, with eyelid ptosis and/or ophthalmoparesis, is the most common feature of mitochondrial disorders, with a frequency of >40% in our database (≈50% if we exclude patients with LHON).
Interestingly, we observed that among our 722 genetically defined patients (see Fig. 1 ), ocular myopathy was positively associated with mtDNA single deletions and POLG mutations, whereas it was less common in patients with OPA1 mutations and all of the mtDNA point mutations.
The association data suggest that when the family history does not point to a specific inheritance pattern, in a patient with suspected mitochondrial disorder and ptosis/ ophthalmoparesis we should first consider a mtDNA single deletion or POLG mutations, whereas a mtDNA point mutation should be suspected in the absence of ocular myopathy (Fig. 3) .
Ocular myopathy may be a feature of a multisystem mitochondrial encephalomyopathy, when associated with central neurological signs such as myoclonus (MERRF), stroke-like episodes (MELAS), cognitive impairment and ataxia (Kearns-Sayre syndrome) and others; however, when it represents the predominant or exclusive sign it is simply denoted as "progressive external ophthalmoplegia" (PEO).
PEO presents at any age with gradually worsening bilateral ptosis and diffuse ophthalmoparesis. Progressive ptosis is typically the earliest and most noticeable feature, often leading to the gradual acquisition of a chin-up compensatory head position [4] . Severe fatigue, depression and pain may contribute to disease impact on the quality of life (QoL) of PEO patients [10] . It has been reported that patients with POLG mutations had more severe QoL impairment than patients with mtDNA mutations or deletions [10] . Importantly, in a study on 23 patients with genetically confirmed PEO, the main finding was decreased respiratory muscle strength, suggesting that periodic assessment of pulmonary function tests, including respiratory muscle strength measurements, should be included in the first evaluation and in the follow-up [11] . We agree with this conclusion; in our group clinically manifest respiratory involvement was observed in 6% of the patients. Of note, in our PEO group there was a higher frequency of swallowing impairment (≈15%). Considering that this is a considerable risk factor for pneumonia, periodic phoniatric assessments for dysphagia may be warranted as well. MRI studies have shown evidence of significant extraocular muscle atrophy, supporting a primary myopathic etiology for the progressive limitation of eye movements defining PEO [12] . Volumetric brain measurements revealed marked cortical brain and cerebellar atrophy among patients with "PEO-plus" phenotypes [13] . However, this [13] and other studies do not provide a clear nosological characterization of "PEO-plus", which is generically defined as the combination of PEO with other "disabling neurological features" [13] . There is therefore the need for a consensual definition of this nosological area to make clinical results comparable and reproducible.
PEO is a clinical feature rather than a definitive diagnosis, which should be at the molecular level. However, as discussed above, there is a strong need of a better definition of the clinical phenotypes of mitochondrial disorders (including ocular myopathies) to obtain a more homogeneous patient categorization, useful in future studies and clinical trials.
In agreement with the clinical practice, we propose that the term "PEO" should denote a neuromuscular disorder with no central neurological features. In case of CNS involvement, ocular myopathy is part of a complex encephalomyopathic syndrome and in our opinion neither "PEO" nor "PEO-plus" are suitable definitions.
We propose here to define as "pure PEO", or simply "PEO", the mitochondrial patients with only ocular myopathy, with no other signs of neuromuscular or multisystem involvement; "PEO-plus" the patients with ocular myopathy and other features of neuromuscular and multisystem involvement with no signs of CNS pathology; and "PEOEncephalomyopathy" the cases characterized by PEO combined with anatomically or physiologically proven involvement of the CNS.
We observed that ocular myopathy with CNS involvement (PEO-encephalomyopathy) was often associated with the m.3243A>G mutation (which should be considered in the diagnostic work-up immediately next to single deletions), whereas "PEO" was associated with single deletions and Twinkle mutations. Rare nuclear and mtDNA mutations were usually associated with complex encephalomyopathic phenotypes (see Table 2 ).
Increased lactate levels were associated with encephalomyopathic phenotypes, and notably they could predict the future development of CNS involvement in patients manifesting isolated PEO at onset. Therefore, the presence of hyperlactacidemia should prompt the follow-up to include a thorough clinical and instrumental CNS examination in these subjects. Scattered COX-negative fibers represent the most frequent histoenzymatic pattern observed on muscle biopsy; however, it is not specific for a definite complex defect, it may occur in all the respiratory chain disorders [14] , and likely does not directly reflect the functional impairment. The lower amount of COX-negative fibers in encephalomyopathic patients can be attributed to the contribution of the MELAS m.3243A>G cases to this group, as this mutation has been consistently associated with predominantly or isolated complex I deficiency and the presence of COX-positive RRF at the muscle biopsy.
In the PEO group, the most commonly associated features were muscle weakness (42.9%), exercise intolerance (23.1%), muscle wasting (17.5%), hearing loss (15.3%) and swallowing impairment (14.9%). Each of these signs and symptoms could not predict the genetic diagnosis, apart from the expected association of severe muscle wasting and TYMP mutations.
"Pure PEO" patients were one third of all PEO patients (see Fig. 1 ), and showed neither different age at onset nor different age at last evaluation, compared to "PEO-plus" patients. The genotype proportions did not significantly differ. Noticeably, the male proportion was significantly lower in pure PEO, with a high statistical significance Fig. 3 Proposed diagnostic work-up: an example. Possible genetic work-up for a patient with suspected mitochondrial disease with or without ptosis/ophthalmoparesis, when the family history is not suggestive for a specific inheritance pattern. NGS next generation sequencing (P < 0.001) (see Table 3 ). Potentially confounding factors (including genotype proportions) did not differ between males and females.
We observed that in our Italian ocular myopathy cohort, the expressivity of mitochondrial disease was higher in male patients. This result is concordant with previous observations, including the higher prevalence of LHON in males [15] and our own data indicating that male gender is a risk factor for the development of stroke-like episodes in Italian m.3243A>G carriers [5] . We are not aware of any potential selection bias, which may explain these findings, considering that these observations are not related and that in our cohort there is a substantial balance between genders. Therefore, we believe that our study reinforces the need for research on the role of gender in mitochondrial diseases.
We are aware that this is an essentially clinical, retrospective, work. Specifically designed basic studies are still needed to elucidate the role of molecular and genetic factors, such as heteroplasmy levels and deletion size for single deletions, mtDNA copy number and multiple deletions in POLG-associated disorders. Furthermore, an ascertainment bias has to be considered. Mild and/or atypical forms (e.g., missing typical features of mitochondrial disorders, such as isolated mild eyelid ptosis) may remain undetected. Therefore, some of these patients could have escaped inclusion in our database. The purely retrospective nature of our study precluded any formal inference on the natural history. However, our registry will allow formal longitudinal studies after an adequate follow-up period of several years, allowing a better understanding not only of the clinical picture but also of the natural history of mitochondrial disorders.
In conclusion, we defined as "pure PEO" the patients with isolated ocular myopathy and "PEO-plus" those with ocular myopathy and other features of neuromuscular and multisystem involvement (excluding CNS). In case of CNS disease, ocular myopathy is part of a complex encephalomyopathy and we propose the term "PEO-encephalomyopathy". The phenotype definitions here revisited may contribute to a more homogeneous patient categorization, which will be useful in future studies (including next generation sequencing technologies) and clinical trials.
